Download the white paper to learn more.
Artificial intelligence is transforming the pharmaceutical industry, accelerating discovery, streamlining clinical development and unlocking new commercial insights. But in a highly regulated, high-stakes environment, success depends on more than advanced algorithms. This whitepaper explores why high-quality, verified and properly licensed content has become essential infrastructure for safe, effective AI in pharma. Drawing on insights from Taylor & Francis and industry experts, it highlights the risks of relying on generic or unverified data and outlines how forward-thinking organizations are building robust content, governance and licensing strategies to support AI at scale. From navigating evolving global regulations to ensuring traceability and human oversight, the paper makes a compelling case for treating content as a strategic asset.
This whitepaper will cover:
- The rapid evolution of global regulations and the need for proactive governance and licensing strategies
- Why leading organizations are treating content as strategic infrastructure rather than a byproduct
- The continuing importance of human oversight for explainability, accuracy and compliance
- How a strong AI strategy begins with defined use cases, mapped content needs and clearly licensed data
For pharma leaders seeking to reduce risk, improve outcomes and realize the full promise of AI, this report provides a practical roadmap for building compliant, high-performing AI systems.
Offered Free by: Taylor & Francis, Inc.
See All Resources from: Taylor & Francis, Inc.
